Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

NCT04832776 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04832776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04832776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
April 17, 2021
Completion date
December 31, 2025
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastasis colon cancer